Spartalizumab or placebo in combination with dabrafenib and trametinib in patients with <i>BRAF</i> V600-mutant melanoma: exploratory biomarker analyses from a randomized phase 3 trial (COMBI-i) - Concepedia

Concepedia

Publication | Open Access

Spartalizumab or placebo in combination with dabrafenib and trametinib in patients with <i>BRAF</i> V600-mutant melanoma: exploratory biomarker analyses from a randomized phase 3 trial (COMBI-i)

DOI Full Paper Access

23

Citations

30

References

2022

Year

Hussein A. Tawbi, Caroline Robert, Jan C. Brase, Daniel Gusenleitner, Eduard Gasal, James E. Garrett, Alexander Savchenko, Güllü Görgün, Keith T. Flaherty, Antoni Ribas,

Journal for ImmunoTherapy of Cancer

Abstract

NCT02967692.

References

	Year	Citations

Page 1